Specialty Pharmacy

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the health care landscape.

Daratumumab (Darzalex, Janssen) is indicated for use in combination with lenalidomide and dexamethasone for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Eculizumab (Soliris) is indicated for adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.

Officials with the FDA have approved Dova Pharmaceuticals’ supplemental New Drug Application (sNDA) for expanding the use of avatrombopag (Doptelet).

Data from a phase 2 study demonstrated that topical ruxolitinib cream significantly improved repigmentation of facial lesions in adults with vitiligo.

Top news of the day from across the health care landscape.

Matthew Malachowski, PharmD, BCPS, supervisor of specialty pharmacy services at UAB Health System, discusses the journey of implementing specialty pharmacy services in a health system.

Dupilumab (Dupixent) is the first biologic medicine approved for inadequately controlled chronic rhinosinusitis with nasal polyposis.

To date, the Ohio audit is the first comprehensive review of PBM practices and incorporated 39 million drug transactions, the authors said.

The recently-finalized CMS drug pricing rule excluded direct and indirect remuneration fee reform.

Certain HER2-positive breast cancers may benefit from anti-HER2 therapy alone without the need for chemotherapy.

Top news of the day from across the health care landscape.

A phase 2a study is evaluating cerdulatinib, an oral SYK/JAK inhibitor, in pre-treated patients with relapsed/refractory follicular lymphoma.

Top news of the day from across the health care landscape.

The new syringe is designed to improve the subcutaneous administration of lanreotide (Somatuline Depot, Ipsen Biopharmaceuticals).

The supplemental New Drug Application supports the expansion of niraparib’s indication as a late-line therapeutic option for patients with ovarian cancer.

Compared with nontargeted therapy, targeted therapies demonstrated a survival advantage for patients 65 years and older with metastatic renal cell carcinoma.

Receptor-modified T cells successfully controlled chronic hepatitis B virus, showing promise as a potential cure for the disease.

Top news of the day from across the health care landscape.

This approval expands tezacaftor/ivacaftor’s indication to include patients ages 6 and older with cystic fibrosis who have certain genetic mutations.

Patients with multiple sclerosis who switched disease-modifying treatments at least twice had a higher relative risk of developing cancer.

Officials with the FDA have approved Allergan’s supplemental biologics application (sBLA) for onabotulinumtoxinA (Botox) for the treatment of children, ages 2 to 17 years, with upper limb spasticity.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

2019 Pharmacy Quality Alliance Annual Meeting included discussions on measures to improve medication services and how pharmacists can play a larger role in the multidisciplinary care team.

Top news of the day from across the health care landscape.

Investigators find visuals more effective than language when prompting people to self-screen for melanoma.